PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Nov 2016 17:01

RNS Number : 0256P
GW Pharmaceuticals PLC
11 November 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW PHARMACEUTICALS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

FMR LLC

4. Full name of shareholder(s)  (if different from 3.):iv

See Section 9

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

10 November 2016

6. Date on which issuer notified:

11 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Indirect

Direct xi

Indirect xii

Direct

Indirect

 

GB0030544687

15,685,800

15,685,800

14,715,180

14,715,180

4.86%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

Right of Recall

6,404,400

2.12%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

21,119,580

6.98%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Controlled Undertaking

Percentage Holding

Fidelity Institutional Asset Management Trust Company

0.03

FMR CO., INC

6.95

Grand Total

6.98

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will acquire:

12. Date on which proxy holder will acquire voting rights:

13. Additional information:

14. Contact name:

Sally-Ann Hatton

15. Contact telephone number:

 

fil-regreporting@fil.com, 01737 837148

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAXFFFEEKFFF
Date   Source Headline
8th Sep 20152:37 pmRNSBlock Listing Application
17th Aug 20159:14 amRNSBlocklisting Interim Review
6th Aug 201512:28 pmRNSThird Quarter 2015 Financial Results
6th Aug 201511:45 amRNSFDA Fast Track and EMA Orphan Designations for CBD
23rd Jul 201512:00 pmRNSNotice of Results
16th Jul 20154:15 pmRNSAppointment of Director
16th Jul 201510:40 amRNSHolding(s) in Company
9th Jul 20154:57 pmRNSHolding(s) in Company
9th Jul 20154:24 pmRNSHolding(s) in Company
7th Jul 20153:23 pmRNSHolding(s) in Company
30th Jun 20157:00 amRNSDirector/PDMR Shareholding
24th Jun 20155:56 pmRNSDirector/PDMR Shareholding
12th Jun 20155:39 pmRNSDirector/PDMR Shareholding
11th Jun 201512:00 pmRNSSecond Ph3 Pivotal Study of Epidiolex in LGS
1st Jun 201510:19 amRNSBlock Listing Application
1st Jun 20157:54 amRNSHolding(s) in Company
1st Jun 20157:53 amRNSHolding(s) in Company
29th May 201511:13 amRNSHolding(s) in Company
19th May 201512:00 pmRNSAppoints US Executive; Relocates CEO to US
15th May 20155:43 pmRNSPurchase of Additional American Depositary Shares
11th May 20153:00 pmRNSPresenting at BAML 2015 Healthcare Conference
11th May 201512:00 pmRNSHalf Yearly Report
11th May 201512:00 pmRNSInitiates Ph3 Pivotal Study of Epidiolex in LGS
11th May 201511:45 amRNSHolding(s) in Company
11th May 201511:45 amRNSHolding(s) in Company
8th May 20154:22 pmRNSHolding(s) in Company
6th May 201512:00 pmRNSNotice of Results
6th May 201512:00 pmRNSInitiates Phase 2 Trial of CBDV in Epilepsy
6th May 20157:01 amRNSClosing of U.S. Public Offering of ADSs
1st May 20153:28 pmRNSHolding(s) in Company
1st May 20157:30 amRNSHolding(s) in Company
29th Apr 20157:00 amRNSPricing of U.S. Public Offering of ADSs
28th Apr 20157:00 amRNSProposed Public Offering of ADSs
27th Apr 201512:00 pmRNSUS Patent Allowance for Use of Cannabidivarin
24th Apr 201512:00 pmRNSOrphan Drug Designation for CBD in NHIE
23rd Apr 20157:00 amRNSNew Physician Reports of Epidiolex Treatment
21st Apr 201512:00 pmRNSStarts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome
14th Apr 20157:00 amRNSNew Epidiolex Data Released by AAN
1st Apr 20152:03 pmRNSHolding(s) in Company
31st Mar 201512:00 pmRNSStarts Ph 3 Trial for Epidiolex in Dravet Syndrome
17th Mar 20155:18 pmRNSHolding(s) in Company
17th Mar 20155:15 pmRNSHolding(s) in Company
25th Feb 201512:00 pmRNSPresenting at Upcoming Investor Conferences
17th Feb 20153:25 pmRNSBlocklisting Interim Review
16th Feb 20153:52 pmRNSHolding(s) in Company
16th Feb 20153:48 pmRNSHolding(s) in Company
9th Feb 20155:31 pmRNSDirector/PDMR Shareholding
5th Feb 20152:25 pmRNSResult of AGM
5th Feb 201512:00 pmRNSPresents at Leerink Global Healthcare Conference
4th Feb 201512:01 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.